Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01461824 · ClinicalTrials.gov registry record · Phase 3

Drug Exposure and Depot Medroxyprogesterone Acetate (DMPA) in Adolescent Subjects

A Phase 3 study, sponsored by Nationwide Children's Hospital.

Completed
Registry status
Phase 3
Development phase
34
Enrollment target

NCT01461824 is a Phase 3 study that has completed, run by Nationwide Children's Hospital. The registered enrollment target is 34 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01461824, a Phase 3 study, has completed, sponsored by Nationwide Children's Hospital.

COMPLETED
Registry status
Phase 3
Development phase
34 participants
Enrollment target

Study Summary

The investigators are doing this study to look at how different doses of the Depot medroxyprogesterone acetate (DMPA) shot effect weight gain and bone mineral density in teens. The investigators hope that what the investigators learn from this study will be used to develop ways to keep girls from gaining weight or losing bone density when receiving DMPA.

Interventions

  • DRUG Depot medroxyprogesterone acetate (DMPA)

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2011-09
Est. Completion 2016-07
Phase Phase 3

Sponsor

Nationwide Children's Hospital

188 total trials

What the Registry Record Tells You About NCT01461824

The ClinicalTrials.gov registry entry for NCT01461824 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nationwide Children's Hospital, which has 188 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Depot medroxyprogesterone acetate (DMPA) is the first listed.

NCT01461824 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01461824 about?

NCT01461824 is a clinical study titled "Drug Exposure and Depot Medroxyprogesterone Acetate (DMPA) in Adolescent Subjects". The investigators are doing this study to look at how different doses of the Depot medroxyprogesterone acetate (DMPA) shot effect weight gain and bone mineral density in teens. The investigators hope that what the investigators learn from this study will be used to develop ways to keep girls from ga...

What is the current status of trial NCT01461824?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 34 participants. The study started on 2011-09. Estimated completion is 2016-07.

What interventions are being tested in trial NCT01461824?

The interventions under investigation include: Depot medroxyprogesterone acetate (DMPA) (DRUG).

Who is sponsoring clinical trial NCT01461824?

This trial is sponsored by Nationwide Children's Hospital, which has 188 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.